Skip to main content
. Author manuscript; available in PMC: 2018 Dec 9.
Published in final edited form as: Leukemia. 2018 Jun 8;33(1):181–190. doi: 10.1038/s41375-018-0169-y

Figure 4. Inhibition of PTPN11-mutant and CBL-mutant hematopoietic progenitor myeloproliferation with kinase inhibitors.

Figure 4

Day 8 CD43+41+235+ hematopoietic progenitors from (A) control, (B) PTPN11, and (C) CBL iPSC lines were cultured in methylcellulose with DMSO, MEK inhibitors (PD901, trametinib), JAK inhibitors (momelotinib, ruxolitinib), or PI3K pathway inhibitors (idelalisib, rapamycin) at EC50 doses and with the specified concentrations of GM-CSF. Colonies were enumerated after 14 days in culture, and data were normalized to maximal colony growth for the DMSO control for each iPSC line (y-axes). Experiments were performed in triplicate with data depicted as means (symbols) with standard error (bars). Statistical analyses were performed with two-way ANOVA and the Dunnett post-test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.